Pharmacogenetic and microRNA mechanisms of beta blocker use on bone
Study context
- Population
- Postmenopausal women in a pilot RCT of beta blocker (BB) on bone turnover markers (BTMs) and BMD over 20 wk, Mayo ClinicMicroRNA (miRNA): 24 (atenolol/placebo)
- Comparison
- Atenolol vs placebo; BB vs placebo
Methodological detailsplacebo-controlled, single-centre (Mayo Clinic), 20 wk, All participants genotyped; miRNA sequencing at baseline and 20 wk
- Placebo-controlled
- Single-centre (Mayo Clinic)
- 20 wk
- All participants genotyped; miRNA sequencing at baseline and 20 wk
Primary result
As reported in the abstract
Pharmacogenetic and miRNA effects of BB on bone · 20 wk
- Several variants in ADRB1, ADRB2 and HDAC4 showed significant pharmacogenetic effects with BMD at multiple sites and with BTMs
- Significant treatment effect for miR-19a-3p over time with atenolol in low responders vs placebo
- Many miRNAs up-regulated over the trial in low responders but not high responders vs placebo
Further findings
Response to atenolol for cardiovascular traits (pulse, blood pressure) vs CTX response
- Largely independent effect
Original publication
Pharmacogenetic and microRNA mechanisms of beta blocker use on bone. J Bone Miner Res. Published 13 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →